☆ 4.7 Article

Obeticholic acid as a second-line treatment for low phospholipid-associated cholelithiasis syndrome

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Related references

Note: Only part of the references are listed.

Review Gastroenterology & Hepatology

Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases

Frederik Nevens et al.

Summary: The discovery of nuclear receptors and transporters has contributed to the development of new drugs for the treatment of cholestatic liver diseases, particularly in the field of second-line therapies for PBC. These new drugs can target cholestasis, fibrogenesis, immune-mediated action, and symptom relief. Obeticholic acid is currently the only approved second-line therapy for PBC, while other drugs in late-stage clinical development include peroxisome proliferator-activated receptor agonists, norursodeoxycholic acid, and NADPH oxidase 1/4 inhibitors.

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Review Genetics & Heredity

Genetic Analysis of ABCB4 Mutations and Variants Related to the Pathogenesis and Pathophysiology of Low Phospholipid-Associated Cholelithiasis

Helen H. Wang et al.

Summary: This review summarizes the role of the ABCB4 gene and its mutations in low phospholipid-associated cholelithiasis, and explores the potential of gene therapy for this disease.

GENES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities

Catherine Dong et al.

Summary: In the largest case-control study of patients with LPAC syndrome, it was found that LPAC syndrome accounted for around 1% of all patients admitted for symptomatic gallstones, and was associated with lower body mass index, higher common bile duct stone prevalence, and lower incidence of acute cholecystitis in addition to established characteristics of the syndrome. About half of LPAC patients had ABCB4 gene variations, which were linked to common bile duct stones and personal or family history of hepato-biliary cancer.

JHEP REPORTS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis

Pierre-Antoine Soret et al.

Summary: The study demonstrated that triple therapy with UDCA, OCA, and fibrates can normalize biochemical liver tests and improve pruritus in patients with difficult-to-treat PBC.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Obeticholic acid may increase the risk of gallstone formation in susceptible patients

Samer Al-Dury et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi et al.

LANCET (2019)

Add to Collection

Article Gastroenterology & Hepatology

Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid

Noortje Ijssennagger et al.

JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway

M. Nakamuta et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)

Add to Collection

Article Gastroenterology & Hepatology

Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones

Helen H. Wang et al.

GASTROENTEROLOGY (2008)

Add to Collection

Article Gastroenterology & Hepatology

Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans

Peter Kovacs et al.

JOURNAL OF HEPATOLOGY (2008)

Add to Collection

Review Genetics & Heredity

Low phospholipid associated cholelithiasis:: association with mutation in the MDR3/ABCB4 gene

Olivier Rosmorduc et al.

ORPHANET JOURNAL OF RARE DISEASES (2007)

Add to Collection

Article Pharmacology & Pharmacy

Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients

N Roglans et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)

Add to Collection

Article Biochemistry & Molecular Biology

Prevention of cholesterol gallstone disease by FXR agonists in a mouse model

A Moschetta et al.

NATURE MEDICINE (2004)

Add to Collection

Article Biochemistry & Molecular Biology

Farnesoid X receptor activates transcription of the phospholipid pump MDR3

L Huang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

Add to Collection

Article Gastroenterology & Hepatology

ABCB4 gene mutation-associated cholelithiasis in adults

O Rosmorduc et al.

GASTROENTEROLOGY (2003)

Add to Collection

Article Gastroenterology & Hepatology

MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis

O Rosmorduc et al.

GASTROENTEROLOGY (2001)

Add to Collection

Article Gastroenterology & Hepatology

Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation epidemiological - Study in an unselected population

FX Caroli-Bosc et al.

DIGESTIVE DISEASES AND SCIENCES (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.